^ the CDC data is next to useless. I've shared a few stories about that. Here's yet another one:
The U.S. Centers for Disease Control and Prevention (CDC) and several state health departments have been reporting COVID-19 diagnostic tests and antibody tests as one grand tally, rather than keeping their results separate, The Atlantic reported.
Reporting these numbers as a lump sum, rather than two distinct data points, presents several major issues.
Namely, combining the numbers could make America's diagnostic testing capabilities and testing rates appear higher than they actually are, according to The Atlantic. And as the tests serve profoundly different purposes, "positive" results from either test cannot be interpreted in the same way. Reporting all the positive results together, as one number, could skew our understanding of how many new COVID-19 cases emerge over time — a crucial metric to help control outbreaks as states begin reopening.
When told how the CDC chose to lump the results of both tests together, director of the Harvard Global Health Institute Ashish Jha told The Atlantic, "You've got to be kidding me ... How could the CDC make that mistake? This is a mess."
https://www.livescie...body-tests.htmlPeer-reviewed findings were published late Friday from one of the key trials of remdesivir, perhaps the most promising antiviral agent for COVID-19, confirming and extending topline results announced a month ago via press release.
Hospitalized patients with COVID-19 who received remdesivir had a median recovery time of 11 days versus 15 days with placebo (rate ratio for recovery 1.32, 95% CI 1.12-1.55, P<0.001), reported John Beigel, MD, of the National Institute of Allergy and Infectious Diseases (NIAID), and colleagues.
Mortality estimates by 14 days were lower for the remdesivir group compared to placebo, but non-significant (HR for death 0.70, 95% CI 0.47-1.04), the authors wrote in the New England Journal of Medicine.
Interestingly, when researchers examined outcomes on an 8-point ordinal scale, they found patients with a baseline ordinal score of 5 had a rate ratio for recovery of 1.47 (95% CI 1.17-1.84), while patients with a baseline score of 7 had a rate ratio for recovery of 0.95 (95% CI 0.64-1.42).
Some of these data were released by the NIAID on April 29, but without further details such as 95% confidence intervals. On May 1, the FDA agreed to let remdesivir be used clinically under an emergency use authorization. Since then, however, clinicians and other researchers have clamored for a fuller report, to help guide their clinical practice. For example, questions were raised as to whether particular subgroups got more benefit from the drug than others.
https://www.medpaget...e/covid19/86670As the world remains in almost a standstill and silenced after being ravaged by the novel coronavirus, scientists worldwide are sprinting to find solutions by researching vaccines and therapeutics. A Chinese research team spearheaded by Peking University (PKU) is taking the lead by unsheathing neutralizing antibodies, which will likely lay the foundation for potent COVID-19 treatment that would hopefully be available as early as this winter, in case of a resurgence of the virus.
The research team led by Sunney Xie, the director of the Beijing Advanced Innovation Center for Genomics at PKU, has successfully identified multiple highly potent neutralizing antibodies against the novel coronavirus SARS-CoV-2, the causative virus of the respiratory disease COVID-19, from convalescent plasma by high-throughput single-cell sequencing.
Such a drug would hopefully be able to stop the COVID-19 pandemic, in case the vaccine isn't available soon, Xie said in an exclusive interview with the Global Times on Wednesday.
*snip*
Xie's team is working with WuXi Biologics, a Hong Kong-listed company, on clinical trials for the drug, which are expected to start in July in some foreign countries such as Australia. Not too many patients are available for testing in China, according to news portal yicai.com.
longish
http://www.globaltim...t/1189193.shtmlBEIJING (Reuters) - The United States should stop wasting time in its fight against the coronavirus and work with China to combat it, rather than spreading lies and attacking the country, the Chinese government’s top diplomat Wang Yi said on Sunday.
*snip*
“Regretfully, in addition to the raging coronavirus, a political virus is also spreading in the United States. This political virus is using every opportunity to attack and smear China,” said Wang, who is also China’s foreign minister.
https://www.reuters....e-idUSKBN230076The crowded Gaza Strip recorded its first death from the coronavirus on Saturday, officials said, amid fears an outbreak could paralyze the territory's already overstretched health care system.
The Palestinian health ministry said the deceased was a 77-year-old woman who had underlying health problems and had been placed at a special field hospital near the Rafah border crossing point upon arriving from Egypt.
https://www.ynetnews...ticle/HJmGvpLiIEnergy companies have been slashing exploration and production budgets since the Covid-19 pandemic took hold and sent oil prices tumbling, but, with few profitable investment alternatives, operators are now likely to increase spending in decommissioning work. Rystad Energy estimates the total value of the global pool of decommissioning projects that will accumulate through 2024 could reach $42 billion. With an average asset age of 25 years, the Northwest European decommissioning market could grow 20% in annual commitments through 2022 if the current low oil prices don’t show signs of substantial recovery soon. In addition to a rapidly maturing asset base and low oil prices that erode commercial viability and potential life extensions, the North Sea decommissioning market will also be helped by favorable service contract prices.
https://oilprice.com...rough-2024.html